Most of these companies are private biotech companies that are out for making profits, and they want to have the ability later on down the road -- when this eventually (generates) cures -- tobe the ones who profit from it.
As of June 30, 16.7% of the entire float of Green Mountain shares were sold short by market players who had hoped toprofit by replacing borrowed shares with ones that they thought would be cheaper in the future.